Pharmaceutical manufacturers are still investing in Europe despite tariffs and lagging behind China and the US, as European locations offer a chance to diversify biopharma suppliers. Planned investments in the EU for the period 2025–2029 reach 164.8 billion euros. The European Commission highlights that the EU has been a leader in this field for decades thanks to a strong knowledge base and know-how, but is losing its lead to other world players in investing in research and innovation. The European Federation of the Pharmaceutical Industry and Associations (EFPIA) warns that without deeper reforms there is a risk of research, development and production moving outside the European area. The Association of the Innovative Pharmaceutical Industry supports increasing EU competitiveness by strengthening the roles of innovation and research. In the Strategic Agenda 2024–2029, the European Council undertakes to support the competitiveness of the EU with an emphasis on innovation and research in healthcare and medicines. Draghi proposes nine specific measures to preserve and expand the EU's capacity for research and development, which will affect the location of production.[1][3]